KCNA2 Variants in Epilepsy: Focusing on Spike-and-Wave Activation in Sleep

Area of Science:

• Genetics
• Neurology
• Epilepsy Research

Background:

• Clinical manifestations and genotype-phenotype correlations of KCNA2 variants in epilepsy patients, especially those with spike-and-wave activation in sleep (SWAS), are not well understood.
• KCNA2 gene variants are increasingly recognized in epilepsy etiologies.

Purpose of the Study:

• To investigate the clinical characteristics and genotype-phenotype correlations of KCNA2 variants in epilepsy patients.
• To determine the association between KCNA2 variants and SWAS.
• To analyze treatment outcomes for patients with SWAS related to KCNA2 variants.

Main Methods:

• Analysis of clinical data from 18 epilepsy patients with KCNA2 variants.
• Comprehensive literature review of 77 epilepsy patients with KCNA2 variants.
• Genotype-phenotype correlation analysis based on variant localization.
• Summary and analysis of clinical characteristics and treatment of 14 patients with SWAS.

Main Results:

• Epilepsy was present in all 18 patients, with a median seizure onset at 6 months; 83.3% had intellectual disability and 77.8% had developmental delay.
• Variants in the pore domain correlated with motor disorders (P=0.007) and SWAS (P<0.001), while S1-S4 variants were linked to MRI abnormalities (P=0.049).
• Of 14 patients with SWAS, only 42.9% responded to treatment, and 28.6% developed drug-resistant epilepsy; valproic acid was common, and combination therapies showed promise.

Conclusions:

• Pathogenic KCNA2 variants are strongly associated with SWAS in epilepsy patients.
• The high prevalence of SWAS in patients with KCNA2 variants underscores the importance of genetic testing for this condition.
• Further research into genotype-specific treatments for KCNA2-related epilepsy is warranted.